产品名称
(±)-磺吡酮, analytical standard
InChI key
MBGGBVCUIVRRBF-UHFFFAOYSA-N
InChI
1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
SMILES string
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4
grade
analytical standard
assay
≥99%
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
cleaning products
cosmetics
food and beverages
forensics and toxicology
personal care
pharmaceutical (small molecule)
veterinary
format
neat
Quality Level
Gene Information
human ... SLC22A12(116085)
正在寻找类似产品? 访问 产品对比指南
Application
有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。
General description
磺吡酮是一种1,3-二羰基尿酸尿酸药物,可用于治疗与痛风有关的高尿酸血症。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Screening of xanthine oxidase inhibitor from selected edible plants and hypouricemic effect of Rhizoma Alpiniae Officinarum extract on hyperuricemic rats
Lin L, et al.
Journal of functional foods, 50(1), 26-36 (2018)
High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites
Holcapek M, et al.
Analytical and Bioanalytical Chemistry, 391(1), 59-78 (2008)
Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9 (UGT1A9)
Kerdpin O, et al.
Drug Metabolism and Disposition, 50(1), 26-36 (2006)
Sharon L Ripp et al.
Drug metabolism and disposition: the biological fate of chemicals, 34(10), 1742-1748 (2006-07-14)
Cytochrome P4503A4 (CYP3A4) is the principal drug-metabolizing enzyme in human liver. Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in decreased exposure to coadministered drugs, with potential loss of efficacy. Immortalized hepatocytes (Fa2N-4 cells) have been proposed as
D H Solomon et al.
Annals of the rheumatic diseases, 67(5), 609-613 (2007-08-31)
Uric acid lowering therapy (UALT) is considered a chronic treatment for gout. Relatively little is known about adherence to UALT. We assessed adherence with UALT over a 1-year study period among 9823 older adults enrolled in a pharmacy benefit program.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持